GSK-2636771

DB11795InvestigationalSmall molecule

GSK2636771 has been used in trials studying the treatment of CANCER, LYMPHOMA, Solid Neoplasm, Recurrent Solid Neoplasm, and Advanced Malignant Neoplasm, among others.

Mechanism: Pharmacologically active on Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform
Curator reviewed
Formula / weight: C₂₂H₂₂F₃N₃O₃ · 433.431 g/mol (avg)
Code names: GSK2636771

Resolves to

Compound

UNIIDW94IAT0LSCAS1372540-25-4ChEMBLCHEMBL3188551PubChem56949517

Structure

InChIKeyXTKLTGBKIDQGQL-UHFFFAOYSA-NSMILESCC1=NC2=C(C=C(C=C2N1CC1=C(C)C(=CC=C1)C(F)(F)F)N1CCOCC1)C(O)=O

Targets

P42338PIK3CB

What you can answer from here — as of June 15, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

39Drug interactionsStructured to mechanism, not free text

6Clinical trialsPhase, status and sponsor resolved per trial

7+ReferencesStructured and connected to the statements they support

Which drugs share a target with GSK-2636771, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account